Denali Therapeutics Inc.

Denali Therapeutics is a clinical-stage biopharmaceutical company dedicated to defeating neurodegenerative and lysosomal storage diseases. The company has pioneered a proprietary TransportVehicle™ (TV) platform designed to enable the delivery of large molecule therapeutics—such as enzymes, antibodies, and oligonucleotides—across the blood-brain barrier (BBB), a significant challenge in treating central nervous system disorders. Headquartered in South San Francisco, Denali leverages human genetics and advanced engineering to develop a broad pipeline of candidates for conditions including Alzheimer’s disease, Parkinson’s disease, ALS, and various lysosomal storage disorders. In March 2026, the company achieved a major milestone with the FDA approval of AVLAYAH™ (tividenofusp alfa-eknm), the first biologic specifically designed to cross the blood-brain barrier.